RESUMO
Introduction: Management of dyslipidemia is an important part of most practice guidelines with many variations between these guidelines. Unfortunately, usually these guidelines are not followed widely on the level of primary care, possibly due to insufficient qualification of health care staff in primary care, non-participation in recent guidelines, and unrealistic target assigned to patients that leads them to non-compliance with medication and follow-up
Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, January 2001, through February 2017. The following search terms were used: dyslipidemia, primary health care dyslipidemia management, follow-up of dyslipidemia.
Aim: In this review, we aimed at evaluating the management expected from primary health care for risk assessment, treatment and follow-up of patients with dyslipidemia
Conclusion: Many guidelines exist for the proper management of dyslipidemia in the primary care setting. Screening is crucial for preventing the cardiovascular sequelae of dyslipidemia. Management modalities include lifestyle modification and pharmacotherapy, while the significance of follow-up cannot be neglected
RESUMO
Introduction: The pathway of glycogen metabolism is regulated by many hormones such as insulin, glucagon, and corticosteroids. Glycogen storage diseases [GSD] most commonly affect muscles, liver, or both and occur in each 20000 to 43000 live birth. They are classified into 12 subtypes, but types I, II, and IX are the most common
Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, from January 2001, through February 2017. The following search terms were used: glycogen storage diseases, Von Gierke disease, Pompe's disease, Cori Disease, Forbes disease, Andersen's disease, McArdle disease, neonatal hypoglycemia, neonatal hepatomegaly
Aim: In this review, we aim to study the genetic basis, diagnosis, presentation, and different management approach to various common types of glycogen storage diseases prevalent in pediatric population
Conclusion: There are no cures for any type of glycogen storage diseases presently. Most treatments are designed to control signs and symptoms. The overall goals are primarily avoiding hypoglycemia, hyperlactatemia, hyperuricemia, and hyperlipidemia. Liver transplantation should be deliberated for patients with GSD type IV and for other progressive hepatic types of GSDs in order to avoid hepatic failure or malignancy. More research must be carried out to develop newer and more effective ways of management
RESUMO
Introduction: The pathway of glycogen metabolism is regulated by many hormones such as insulin, glucagon, and corticosteroids. Glycogen storage diseases [GSD] most commonly affect muscles, liver, or both and occur in each 20000 to 43000 live birth. They are classified into 12 subtypes, but types I, II, and IX are the most common
Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, from January 2001, through February 2017. The following search terms were used: glycogen storage diseases, Von Gierke disease, Pompe's disease, Cori Disease, Forbes disease, Andersen's disease, McArdle disease, neonatal hypoglycemia, neonatal hepatomegaly
Aim: In this review, we aim to study the genetic basis, diagnosis, presentation, and different management approach to various common types of glycogen storage diseases prevalent in pediatric population
Conclusion: There are no cures for any type of glycogen storage diseases presently. Most treatments are designed to control signs and symptoms. The overall goals are primarily avoiding hypoglycemia, hyperlactatemia, hyperuricemia, and hyperlipidemia. Liver transplantation should be deliberated for patients with GSD type IV and for other progressive hepatic types of GSDs in order to avoid hepatic failure or malignancy. More research must be carried out to develop newer and more effective ways of management
RESUMO
Oxidative stress is a condition that might predispose the individuals to diseases including cancer. The 8- hydroxydeoxyguanosine [8-OHdG] is a marker that reflects oxidative DNA damage in the body. In this study, seven Saudi medicinal plants were investigated for their potential against oxidative DNA damage using the 8-OHdG assay in cultured human lymphocytes. Extracts at 10-100ìg/mL from Nigella sativa black seeds, Olea chrysophylla [aerial parts] and Pulicaria crispa [aerial parts] significantly decreased levels of 8-OHdG [P<0.01], suggesting their usefulness as protective agents against oxidative DNA damage. The order of the antioxidative DNA damage effect of the extracts at 100Mug/mL was Pulicaria crispa [36%] >Olea chrysophylla [24%] >Nigella sativa [18%]. On the other hand, extracts of Bupleurum falcatum L at 100ug/mL induced significant increases in the 8-OHdG biomarker [P<0.01]. Finally, Ficus palmate, Zygophyllum Simplex, Citrullus colocynthis did not modulate levels of 8-OHdG in cultured human lymphocytes at examined concentrations [10 and 100Mug/mL, P>0.05]. In conclusion, extracts from Nigella sativa, Olea chrysophylla and Pulicaria cripa medicinal plants can be used as useful agents to counteract oxidative DNA damage in cultured cells